Company Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab.
The company was founded in 2003 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Robert W. Duggan |
Contact Details
Address: 2882 Sand Hill Road, Suite 106 Menlo Park, California 94025 United States | |
| Phone | 650-460-8308 |
| Website | summittxinc.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President and Director |
| Robert W. Duggan | Co-Chief Executive Officer and Executive Chairman |
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer and Director |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Bhaskar Anand | Chief Accounting Officer and Head of Finance |
| Abby Guzman Murphy | Head of Human Resources |
| Divya Chari | Head of Global Clinical Operations |
| Dave Gancarz | Chief Business and Strategy Officer? |
| Will Black | Head of Information Technology? |
| Dr. Betty Y. Chang Ph.D. | Head of Research, Oncology and Inflammation? |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| Jun 18, 2024 | D | Notice of Exempt Offering of Securities |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K | Current Report |
| May 13, 2024 | 8-K | Current Report |
| May 13, 2024 | 424B5 | Filing |